Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

Status:	Completed
Conditions:	Hospital
Therapuetic Areas:	Other
Healthy:	No
Age Range:	18 - Any
Updated:	12/6/2017
Start Date:	March 2006
End Date:	July 2006

A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will
significantly decrease the number of patients who experience nausea and vomiting after
surgery.

Inclusion criteria:

- History of PONV (postoperative nausea and vomiting) and/or motion sickness.

- Have not smoked for the last 6 months.

- Having certain abdominal, breast, thyroid or shoulder surgery.

Exclusion criteria:

- Pregnant or breastfeeding.

- Have certain pre-existing medical conditions or take certain medications.

We found this trial at

sites

Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

Use our guide to learn which trials are right for you!

A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis

Select your condition

Common Conditions

All Conditions